Nephrol Dial Transplant (2001) 16: 2188-2193
© 2001 European Renal Association-European Dialysis and Transplant Association
Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis
1 Fundación Renal Iñigo Alvarez de Toledo, 2 Fundación Jiménez Díaz and 3 Hospital General Universitario Gregorio Marañon, Instituto Reina Sofía de Investigación Nefrológica, Madrid, Spain
Background. Recent data have suggested the existence of a relationship between the use of synthetic vascular accesses and increased erythropoietin (Epo) requirements. The present study aimed to evaluate the possible role of the type of vascular access in both Epo and intravenous (i.v.) iron requirements.
Methods. One-hundred-and-seven individuals without recognized causes of Epo resistance, 62 of them undergoing chronic haemodialysis through native arteriovenous fistulae (AVF) and 45 through PTFE grafts, were retrospectively studied (one-year follow-up). Sixty-nine patients, i.e. all but three with a PTFE graft and 27 with native AVF, were taking anti-platelet agents. Doses of i.v. iron and Epo and laboratory parameters were recorded.
Results. Erythropoietin and i.v. iron requirements were higher in the patients dialysed through PTFE grafts compared with those with native AVF (Epo: 103.8±58.4 vs 81.0±44.5 U/kg/week, P=0.025; i.v. iron: 178.9±111 vs 125.9±96 mg/month, P=0.01). On a yearly basis, the difference in Epo dose represented a total of 94582±16789 U Epo/patient/year. Moreover, the patients with PTFE grafts received more red blood cell transfusions than patients with native AVF (P=0.021). No differences between laboratory, dialysis kinetics, demographic or comorbidity parameters were found. The type of vascular access was the best predictor of the requirement of 
150 U/kg/week Epo (P=0.03). Even though the patients who received anti-platelet therapy required more i.v. iron (167.5±103.6 vs 114.5±101.4 mg/month, P=0.008) but not more Epo (P=NS), the possibility of an accessory role of anti-platelet agents in the increased Epo requirements with PTFE grafts cannot be ruled out.
Conclusions. The use of a PTFE graft and anti-platelet drugs represents a previously undescribed association related to higher Epo and i.v. iron requirements. The association described herein adds new arguments to the debate concerning the choice of vascular access in chronic haemodialysis patients.
Keywords: anaemia; native fistulae; polytetrafluoroethylene (PTFE) graft
Correspondence and offprint requests to: Carlos Caramelo, MD, Laboratorio de Nefrología, Fundación Jiménez Díaz, Universidad Autónoma, Av. Reyes Católicos n° 2, E-28040 Madrid, Spain. Email: ccaramelo{at}fjd.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Wystrychowski, T. M. Kitzler, S. Thijssen, L. Usvyat, P. Kotanko, and N. W. Levin Impact of switch of vascular access type on key clinical and laboratory parameters in chronic haemodialysis patients Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2194 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E Dar Santos, K. F Shalansky, and J. P Jastrzebski Management of Anemia in Erythropoietin-Resistant Hemodialysis Patients Ann. Pharmacother., December 1, 2003; 37(12): 1768 - 1773. [Abstract] [Full Text] [PDF]
|
|